| Literature DB >> 3709599 |
M L Slevin, V J Harvey, R J Osborne, J H Shepherd, C J Williams, G M Mead.
Abstract
A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.Entities:
Mesh：
Substances：
Year: 1986 PMID： 3709599 DOI： 10.1016/0277-5379(86)90396-2
Source DB: PubMed Journal: Eur J Cancer Clin Oncol ISSN： 0277-5379